Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00525499 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of ASC-J9 Cream in Acne Vulgaris
A Phase 2 study of Acne Vulgaris, sponsored by AndroScience.
- Completed
- Registry status
- Phase 2
- Development phase
- 186
- Enrollment target
- 10
- Study locations
NCT00525499: Completed Phase 2 study of Acne Vulgaris, sponsored by AndroScience.
NCT00525499 is a Phase 2 study of Acne Vulgaris that has completed, run by AndroScience. The registered enrollment target is 186 participants, below the 273-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (32% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00525499, a Phase 2 study of Acne Vulgaris, has completed, sponsored by AndroScience.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 186 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to evaluate if topical ASC-J9 cream is effective in treating acne.
Primary Outcome
Percent change in inflammatory lesion counts from Baseline to Week 12. It is calculated by taking the Week 12 count minus the Baseline count and then dividing by the Baseline count. Thus, a negative percent change will reflect a reduction in lesion counts.
Conditions Studied
Interventions
- DRUG placebo
- DRUG ASC-J9 cream
Study Locations (10)
California
- East Bay Dermatology Medical Group - Fremont
- Therapeutics Clinical Research - San Diego
Texas
- DermResearch, Inc - Austin
- J&S Studies, Inc - Bryan
Idaho
- Northwest Clinical Trial - Boise
New Jersey
- TKL Research, Inc - Paramus
New Mexico
- Academic Dermatology Associates - Albuquerque
Tennessee
- Dermatology Associates - Knoxville
Utah
- Dermatology Research Center, Inc - Salt Lake City
Virginia
- Education and Research Foundation - Lynchburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
What the finished NCT00525499 record still lists
NCT00525499 is an interventional study that assigns participants to a tested intervention. The registered 186 participants enrollment target is mid-sized for trials with a published cap, below the 273-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (32% lower).
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00525499 lists 10 locations in 8 states (California, Texas, Idaho).
Frequently Asked Questions
What is clinical trial NCT00525499 about?
NCT00525499 is a clinical study titled "A Phase 2 Study of ASC-J9 Cream in Acne Vulgaris". The purpose of this study is to evaluate if topical ASC-J9 cream is effective in treating acne.
What is the current status of trial NCT00525499?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 186 participants. The study started on 2007-08. Estimated completion is 2008-07.
What conditions does trial NCT00525499 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT00525499?
The interventions under investigation include: placebo (DRUG), ASC-J9 cream (DRUG).
Who is sponsoring clinical trial NCT00525499?
This trial is sponsored by AndroScience, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00525499 being conducted?
This trial has 10 study locations across California, Idaho, New Jersey, New Mexico, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00525499's enrollment target sits among peer trials
186 29th of 67 higher than 38 of 67 other Acne Vulgaris trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acne Vulgaris trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
ACTIVE NOT RECRUITING · Phase 2
-
Dose Range Study of CD5789 in Acne Vulgaris
COMPLETED · Phase 2
-
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
COMPLETED · Phase 2
-
Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris
COMPLETED · Phase 2
-
Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris
COMPLETED · Phase 2
-
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03567889 · 186 participants · Phase 3
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- NCT05281471 · 186 participants · Phase 3
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- NCT05405595 · 186 participants · Phase 1
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- NCT05762107 · 186 participants · Phase 2
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia